Feed CRL
CR

Charles River Laboratories

CRL · NYSE

$283.53 +1.62% (+$4.52)
1M -6.55%
Market Cap $13.4B
P/E Ratio -
Div. Yield -
ROE 7.72%

Bulios Fair Price

$149.58

47.2% downside

Trenutna cena

$283.53

Podcenjeno Poštena vrednost Precenjeno

Po podatkih Bulios Fair Price je delnica CRL trenutno precenjena glede na svojo tržno ceno. Kako deluje?

Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?

Piotroski F-Score Moderate
5/9
Valuation
25 /100
Expensive
EV/EBITDA 73.82x
P/FCF 36.26x
P/S 3.36x
Growth
50 /100
Stable
Rev. growth 0.33%
Book val. growth 2.07%
FCF growth 20.69%
Profitability
46 /100
Moderate
Gross margin 32.24%
FCF margin 9.27%
Net margin 5.96%
Quality
29 /100
Poor
ROIC 10.00%
Asset turnover 0.53x
ROE 7.72%
Debt
24 /100
High
Debt/Equity 1.07x
Net debt/EBITDA 12.86x
Current ratio 1.35x
Stability
41 /100
Moderate
Beta 1.41x
Profitable years 0
Rev. volatility 3.08%

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o CRL
Online

O podjetju

Charles River Laboratories International, Inc. (CRL) is an American company operating in the biotechnology and pharmaceutical research industry. The company specializes in providing preclinical and clinical services to pharmaceutical and biotechnology companies, academic institutions, and government organizations. Its services include drug testing, toxicity studies, pharmacokinetics, viral safety testing, genetic analysis, and other biological and chemical analyses. Charles River Laboratories has a broad portfolio of laboratory and clinical services that are crucial for the development of new drugs and treatment protocols. The company emphasizes quality, innovation, and ethical standards in its research and laboratory practices. It is recognized as a significant partner for the pharmaceutical and biotechnology sectors. Charles River Laboratories International, Inc. (CRL) shares are publicly traded on the stock exchange and may represent an attractive investment opportunity for investors monitoring the biotechnology and pharmaceutical industry and seeking investments in a company with a significant position in drug research and development.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Medical - Diagnostics & Research

CEO

Birgit Girshick

Employees

19,000

Headquarters

Wilmington

Prihajajoči dogodki

04 NOV.

Earnings

Upcoming earnings report

43d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.